BeyondAirInc . (NASDAQ:XAIR) COO Amir Avniel Sells 5,000 Shares
BeyondAirInc . (NASDAQ:XAIR) COO Amir Avniel sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $6.20, for a total transaction of $31,000.00. Following the completion of the sale, the chief operating officer now owns 507,441 shares in the company, valued at $3,146,134.20. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of NASDAQ XAIR opened at $6.40 on Friday. The company has a 50 day simple moving average of $6.76 and a 200 day simple moving average of $7.06. The firm has a market cap of $105.59 million, a PE ratio of -3.48 and a beta of -0.60. BeyondAirInc . has a 1 year low of $3.45 and a 1 year high of $12.50. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.48 and a quick ratio of 5.48.
BeyondAirInc . (NASDAQ:XAIR) last issued its quarterly earnings data on Monday, June 22nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). BeyondAirInc . had a negative net margin of 203.22% and a negative return on equity of 162.21%. The business had revenue of ($0.20) million during the quarter, compared to the consensus estimate of $0.45 million. As a group, research analysts anticipate that BeyondAirInc . will post -1.21 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on the stock. Oppenheimer restated a “buy” rating and issued a $9.00 price target on shares of BeyondAirInc . in a research note on Tuesday, June 23rd. Zacks Investment Research reiterated a “buy” rating and issued a $9.25 price objective on shares of BeyondAirInc . in a report on Saturday, May 30th. Finally, ValuEngine upgraded shares of BeyondAirInc . from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd.
About BeyondAirInc .
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Read More: Analyzing a company’s cash flow statement
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.